A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)
Doctors are studying a new treatment, Olpasiran, for people who have high levels of a particular type of fat called lipoprotein(a) in their blood. High lipoprotein(a) can increase the risk of heart problems. This research hopes to find out if Olpasiran can stop serious heart events like heart attacks, heart-related deaths, or needing urgent heart surgery. Participants will be split into groups, with some receiving the new medicine and others a dummy treatment (placebo), so doctors can compare the results fairly. The study is in its final stages, meaning it’s a big step towards potentially making this treatment available.
At a glance
What is this study about?
You might be interested in this study if you have concerns about your heart health. This research is focused on a new medicine called Olpasiran. The main goal is to see if Olpasiran can help stop serious heart problems from happening, such as heart attacks, heart-related deaths, or the need for urgent heart bypass surgery. Doctors are particularly interested in people who have high levels of something in their blood called lipoprotein(a).
Lipoprotein(a) is a type of fat in your blood, and high levels of it can increase your risk of developing heart conditions. If you have been told you have high lipoprotein(a), or if heart disease runs in your family, this study might be relevant to you. The scientists want to find out if taking Olpasiran can lower those risks effectively.
This is a large, important study (what doctors call a 'Phase III' study). It means they are confident enough in earlier results to test the medicine on many people to confirm if it really works and is safe. Some people will receive Olpasiran, while others will get a placebo (a dummy treatment that looks like the real medicine but contains no active drug). This helps the researchers understand the true effects of the new medicine.
Key takeaways
- Exploring a new medicine, Olpasiran, for heart health.
- Aims to prevent heart attacks and other serious heart issues.
- Specifically for people with high levels of lipoprotein(a).
- Compares Olpasiran to a dummy medicine (placebo).
- Open to adults aged 18 and over.
- Participation involves regular clinic visits and health checks.
Who may be eligible?
To join this study, you need to be an adult, 18 years old or older. The study is open to both men and women. The main requirement is that you have high levels of a specific type of fat in your blood called lipoprotein(a).
Beyond these basic points, there will be other specific health checks and medical history questions to ensure the study is safe and appropriate for you. For example, the study might look at your existing heart health and any other medications you might be taking.
It's important to remember that even if you meet the main criteria, doctors will need to do a full health check to make sure the study is a good fit for you and that taking part would be safe.
- Are you 18 years old or older?
- Are you able to attend regular clinic appointments?
- Have you been told you have high levels of lipoprotein(a) in your blood?
- Are you comfortable with the possibility of receiving a placebo?
- Are you willing to follow study instructions for medication and visits?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you would be involved for a period of time, which will be explained to you fully. You would be given either the new medicine, Olpasiran, or a placebo (a dummy medicine), but neither you nor your study doctor would know which one you are receiving. This is called a 'double-blind' study and helps make the results fair.
You would have regular visits to the clinic for health check-ups, blood tests, and to ensure you are feeling well and taking the medication as instructed. These visits are important for monitoring your health and the effects of the treatment. The research team will track your health over time, paying close attention to any major heart-related events. All the details about how many visits, what tests are involved, and the total length of your participation would be explained clearly before you agree to join.
Potential risks and benefits
Locations (17)
- —Spain
- —Hungary
- —Portugal
- —Greece
- —Germany
- —Italy
- —Austria
- —Ireland
- —Romania
- —Slovakia
- —Netherlands
- —Czechia
+5 more sites — see the official record for the full list.
Common questions
What is lipoprotein(a)?
Lipoprotein(a) is a type of fat in your blood. High levels can put you at a greater risk of heart disease.
What is a placebo?
A placebo is a 'dummy' treatment that looks like the real medicine but contains no active drug. It's used to compare against the new medicine.
Will I know if I'm getting the real medicine?
No, neither you nor your study doctor will know if you're getting Olpasiran or the placebo. This helps make the study results accurate.
What kind of heart problems is this study looking at?
The study is looking at serious events like heart attacks, heart-related deaths, or needing urgent heart surgery.
Can I stop being in the study if I want to?
Yes, you can choose to leave the study at any point, and it won't affect your regular medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.